Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
Related Questions
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
What is your preferred first-line treatment regimen for patients with high-risk MDS?
For patients with newly diagnosed unmutated CLL how will you decide between BTKi alone vs Ven/BTKi vs Ven/Obin vs Ven/Obin/Acalabrutinib?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?